A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase I/II trial is studying the side effects and best dose of ixabepilone and how well it works in treating patients with recurrent glioma.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Anticonvulsants; Epothilone B; Epothilones

Criteria

Inclusion Criteria:

• Patients must have histologically proven malignant glioma (anaplastic astrocytoma or glioblastoma multiforme) which is progressive or recurrent following radiation therapy +/- chemotherapy; patients with previous low grade glioma who progressed after radiotherapy +/- chemotherapy and are biopsied and found to have a high grade glioma are eligible

• Patients must have measurable progressive or recurrent malignant glioma by MRI or CT imaging

• Patients must have recovered from severe toxicity of prior therapy; an interval of at least 3 months must have elapsed since the completion of the most recent course of radiation therapy while at least 3 weeks must have elapsed since the completion of a non-nitrosourea containing chemotherapy regimen and at least 6 weeks since the completion of a nitrosourea containing chemotherapy regimen

• Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)

• Absolute neutrophil count >= 1500/mm^3

• Platelets >= 100,000/mm^3

• HgB > 9 g/dl

• Creatinine =< 1.5mg/dl

• Total Bilirubin =< 1.5mg/dl

• Transaminases =< 2.5 times above the upper limits of the institutional norm)

• Patients must be able to provide written informed consent

• Patients must have =< 2 prior chemotherapy regimens

• Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception; the anti-proliferative activity of this experimental drug may be harmful to the developing fetus or nursing infant; female patients of child-bearing potential must have a negative pregnancy test

• Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast; patients with prior malignancies must be disease-free for >= five years

• Patients must be maintained on a stable corticosteroid regimen from the time of their baseline scan until the start of treatment

• Patients must have a Mini Mental State Exam score of >= 15

Exclusion Criteria:

• Patients with serious concurrent infection or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety

• Patients who are pregnant or breast-feeding

• Patients with more than 2 prior chemotherapy regimens

• Patients receiving concurrent investigational agents

• Patients receiving any of the following medications which are known to be moderate to significant inhibitors of CYP3A4 are not eligible:

• Antibiotics: clarithromycin, erythromycin, troleandomycin

• Anti-HIV agents: delavirdine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, lopinavir

• Antifungals: itraconazole, ketoconazole, fluconazole (doses > 200mg/day), voriconazole

• Antidepressants: nefazodone, fluvoxamine

• Calcium channel blockers: verapamil, diltiazem

• Miscellaneous: amiodarone NOTE: The above list of agents was provided by the National Cancer Institute as moderate to significant inhibitors of CYP3A4 that should not be administered with BMS; there may be other agents that have similar activities on CYP3A4, however these are currently unspecified; if investigators are concerned about a particular medication's inhibitory effect on CYP3A4, they are encouraged to consult local pharmacy services for more information and to contact the principal investigator to discuss the situation further